CompletedNot applicableNCT01606826
Official study title

Severe Asthma Research Program

Study summary

The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forAsthma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 14, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Milton S. Hershey Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Milton S. Hershey Medical Center
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Asthmatic Patients: 1. Physician diagnosis of asthma, 2. Age 6 years and older 3. Evidence of historical reversibility, including either:
  • FEV1 bronchodilator reversibility ≥ 12%, or
  • Airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL.
Reasons someone may not be able to joinExclusion criteria

1. Pregnancy during the characterization phase, 2. Current smoking, 3. Smoking history \> 10 pack years if ≥30 years of age, or smoking history \> 5 pack years if \<30 years of age (Note: if a subject has a smoking history, no smoking within the past year), 4. Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways, 5. History of premature birth before 35 weeks gestation, 6. Unwillingness to receive an intramuscular triamcinolone acetonide injection, 7. Evidence that the participant or family may be unreliable or poorly adherent to their asthma treatment or study procedures, 8. Planning to relocate from the clinical center area before study completion, 9. Any other criteria that place the subject at unnecessary risk according to the judgment of the Principal Investigator and/or attending physician(s) of record, or 10. Currently participating in an investigational drug trial for asthma therapies. Healthy Controls: Inclusion criteria: Healthy subjects between the age of 18 and 65 years.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of California, San FranciscoSan Francisco, California
  • Brigham & Women's HospitalBoston, Massachusetts
  • Children's Hospital, BostonBoston, Massachusetts
  • Washington UniversitySt Louis, Missouri
  • Wake Forest University Health SciencesWinston-Salem, North Carolina
  • Cleveland ClinicCleveland, Ohio
  • University of PittsburghPittsburgh, Pennsylvania
  • University of Wisconsin-MadisonMadison, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 14, 2026. Always confirm current availability with the study team.

View original record ↗